A new ethical solution may mitigate the moral quandary which often hampers stem cell research
Human embryonic stem cells (hESC’s) hold tremendous promise for cell therapies for a range of degenerative diseases. Cost-effective treatment that is affordable by public health systems will only be possible if allogenic tissue banks are stocked with high quality clinical grade hESC’s. Access to these cell lines for the research and development of these cell treatments is of vital importance in the fight against many debilitating and fatal diseases.
The University of Manchester has developed technology which comprises six high quality, ethically sourced Clinical/GMP grade hESC lines known as MAN 11-MAN 16. Derived from fresh surplus human embryos, the cell lines avoid the common moral and ethical concerns due to them being designated poor quality during the IVF selection process. Although these embryos do not meet the standards to be viable IVF implantable embryos they are perfectly suited for cell line derivation.
• Embryo and cell line derivation to GMP
• Non-viable embryos used, avoiding typical ethical concerns
• Xeno-free GMP protocol
• MAN-15 HLA-type universal donor
• Sibling lines available
• EUTCD standard
The cell lines are currently available for licensing on both research and development and commercial terms.